 Tarak Srivastava
Concepts (407)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrotic Syndrome | 20 | 2024 | 29 | 4.380 |
Why?
| | Podocytes | 10 | 2021 | 12 | 3.700 |
Why?
| | Kidney Glomerulus | 13 | 2024 | 19 | 3.610 |
Why?
| | Glomerulosclerosis, Focal Segmental | 15 | 2024 | 22 | 3.300 |
Why?
| | Glomerular Filtration Rate | 9 | 2021 | 114 | 3.140 |
Why?
| | Receptors, Prostaglandin E, EP2 Subtype | 5 | 2022 | 5 | 3.120 |
Why?
| | Renal Insufficiency, Chronic | 8 | 2023 | 193 | 2.770 |
Why?
| | Dinoprostone | 6 | 2022 | 8 | 2.270 |
Why?
| | Stress, Mechanical | 7 | 2021 | 9 | 2.050 |
Why?
| | Humans | 80 | 2024 | 6929 | 1.990 |
Why?
| | Calcimimetic Agents | 4 | 2018 | 7 | 1.890 |
Why?
| | Kidney | 11 | 2024 | 94 | 1.860 |
Why?
| | Male | 51 | 2024 | 3367 | 1.760 |
Why?
| | Creatinine | 8 | 2022 | 52 | 1.730 |
Why?
| | Nephrosis, Lipoid | 6 | 2024 | 6 | 1.660 |
Why?
| | Calcium | 8 | 2018 | 40 | 1.620 |
Why?
| | Animals | 17 | 2024 | 741 | 1.600 |
Why?
| | Mechanotransduction, Cellular | 3 | 2021 | 5 | 1.580 |
Why?
| | Diphosphonates | 8 | 2012 | 13 | 1.480 |
Why?
| | Female | 42 | 2024 | 3534 | 1.370 |
Why?
| | Hypercalciuria | 4 | 2009 | 4 | 1.320 |
Why?
| | Child | 47 | 2024 | 3348 | 1.310 |
Why?
| | Familial Hypophosphatemic Rickets | 3 | 2022 | 9 | 1.250 |
Why?
| | Kidney Diseases | 8 | 2023 | 71 | 1.210 |
Why?
| | Mice | 10 | 2024 | 339 | 1.150 |
Why?
| | Hypertension | 6 | 2024 | 65 | 1.130 |
Why?
| | Adolescent | 34 | 2024 | 2183 | 1.120 |
Why?
| | Child, Preschool | 29 | 2024 | 1562 | 1.110 |
Why?
| | Vitamin D | 5 | 2019 | 22 | 1.090 |
Why?
| | beta Catenin | 2 | 2022 | 8 | 1.000 |
Why?
| | Nephrectomy | 5 | 2018 | 15 | 0.980 |
Why?
| | Parathyroid Hormone | 6 | 2018 | 24 | 0.980 |
Why?
| | Living Donors | 2 | 2018 | 7 | 0.930 |
Why?
| | Interleukin-6 | 2 | 2021 | 10 | 0.920 |
Why?
| | Cyclooxygenase 2 | 3 | 2022 | 5 | 0.900 |
Why?
| | Kidney Failure, Chronic | 4 | 2022 | 169 | 0.820 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2021 | 9 | 0.780 |
Why?
| | Kidney Transplantation | 4 | 2023 | 115 | 0.780 |
Why?
| | Proteinuria | 9 | 2024 | 28 | 0.770 |
Why?
| | Glomerulonephritis | 4 | 2021 | 8 | 0.760 |
Why?
| | Pseudohypoparathyroidism | 2 | 2015 | 2 | 0.750 |
Why?
| | Proteoglycans | 1 | 2020 | 2 | 0.740 |
Why?
| | Transcriptional Activation | 1 | 2020 | 10 | 0.740 |
Why?
| | Albuminuria | 5 | 2022 | 12 | 0.740 |
Why?
| | Acute-Phase Reaction | 2 | 2011 | 2 | 0.720 |
Why?
| | Nephrology | 3 | 2022 | 19 | 0.690 |
Why?
| | Infant | 16 | 2024 | 1449 | 0.670 |
Why?
| | Receptors, Prostaglandin E, EP4 Subtype | 2 | 2022 | 2 | 0.660 |
Why?
| | Furosemide | 1 | 2017 | 1 | 0.620 |
Why?
| | Hypercalcemia | 4 | 2012 | 10 | 0.620 |
Why?
| | Hyperparathyroidism, Secondary | 1 | 2017 | 9 | 0.610 |
Why?
| | Urologic Diseases | 1 | 2017 | 3 | 0.600 |
Why?
| | Adult | 18 | 2024 | 1199 | 0.590 |
Why?
| | Eicosanoids | 1 | 2017 | 1 | 0.580 |
Why?
| | Mechanical Phenomena | 1 | 2017 | 1 | 0.580 |
Why?
| | Immunosuppressive Agents | 5 | 2015 | 32 | 0.560 |
Why?
| | Young Adult | 12 | 2024 | 641 | 0.550 |
Why?
| | Mice, Transgenic | 3 | 2024 | 35 | 0.540 |
Why?
| | Bone Remodeling | 1 | 2015 | 1 | 0.540 |
Why?
| | Genetic Predisposition to Disease | 4 | 2020 | 226 | 0.540 |
Why?
| | Urinary Tract Infections | 2 | 2009 | 21 | 0.510 |
Why?
| | Cell Cycle Proteins | 2 | 2006 | 18 | 0.500 |
Why?
| | Blood Pressure | 3 | 2024 | 65 | 0.500 |
Why?
| | Renal Circulation | 1 | 2014 | 6 | 0.490 |
Why?
| | Up-Regulation | 4 | 2020 | 25 | 0.480 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 27 | 0.470 |
Why?
| | Urolithiasis | 2 | 2012 | 2 | 0.460 |
Why?
| | Naphthalenes | 1 | 2013 | 6 | 0.450 |
Why?
| | Obesity | 3 | 2021 | 124 | 0.450 |
Why?
| | Vitamin D Deficiency | 2 | 2019 | 10 | 0.450 |
Why?
| | Receptors, Prostaglandin E, EP1 Subtype | 1 | 2012 | 1 | 0.440 |
Why?
| | Cell Line | 3 | 2021 | 79 | 0.420 |
Why?
| | Treatment Outcome | 8 | 2023 | 649 | 0.410 |
Why?
| | Osteoporosis | 4 | 2012 | 25 | 0.400 |
Why?
| | Cardiovascular Diseases | 2 | 2023 | 49 | 0.400 |
Why?
| | Signal Transduction | 3 | 2017 | 133 | 0.400 |
Why?
| | Microfilament Proteins | 2 | 2001 | 12 | 0.390 |
Why?
| | Bone Diseases, Metabolic | 4 | 2018 | 8 | 0.390 |
Why?
| | Biomarkers | 4 | 2022 | 132 | 0.390 |
Why?
| | Nephroma, Mesoblastic | 1 | 2010 | 1 | 0.380 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2010 | 1 | 0.380 |
Why?
| | Bone Density | 3 | 2012 | 44 | 0.380 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 11 | 0.380 |
Why?
| | Time Factors | 6 | 2015 | 263 | 0.380 |
Why?
| | Disease Progression | 6 | 2023 | 110 | 0.370 |
Why?
| | Phospholipase C gamma | 2 | 2024 | 2 | 0.360 |
Why?
| | Cytokines | 4 | 2017 | 48 | 0.360 |
Why?
| | Kidney Function Tests | 2 | 2012 | 22 | 0.360 |
Why?
| | Citric Acid | 1 | 2009 | 1 | 0.350 |
Why?
| | Nephrolithiasis | 1 | 2009 | 1 | 0.340 |
Why?
| | Hematuria | 1 | 2009 | 7 | 0.340 |
Why?
| | Heptanoic Acids | 1 | 2009 | 1 | 0.340 |
Why?
| | Pyrroles | 1 | 2009 | 1 | 0.340 |
Why?
| | Radioisotope Dilution Technique | 1 | 2009 | 1 | 0.340 |
Why?
| | Mass Spectrometry | 1 | 2009 | 18 | 0.330 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2009 | 13 | 0.330 |
Why?
| | Risk Factors | 6 | 2023 | 490 | 0.320 |
Why?
| | Models, Biological | 1 | 2009 | 63 | 0.320 |
Why?
| | Albumins | 3 | 2022 | 7 | 0.320 |
Why?
| | Disease Models, Animal | 2 | 2021 | 61 | 0.320 |
Why?
| | Abdominal Pain | 1 | 2009 | 71 | 0.310 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 90 | 0.310 |
Why?
| | Rickets | 2 | 2010 | 2 | 0.300 |
Why?
| | Urinary Calculi | 2 | 2005 | 3 | 0.300 |
Why?
| | Biomechanical Phenomena | 2 | 2017 | 8 | 0.300 |
Why?
| | Body Fluids | 1 | 2007 | 1 | 0.290 |
Why?
| | Nitrogen | 1 | 2007 | 1 | 0.290 |
Why?
| | Dialysis Solutions | 1 | 2007 | 19 | 0.290 |
Why?
| | Diagnostic Techniques, Urological | 1 | 2006 | 1 | 0.290 |
Why?
| | Medical Laboratory Science | 1 | 2006 | 1 | 0.290 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2017 | 3 | 0.280 |
Why?
| | Steroids | 2 | 2017 | 16 | 0.280 |
Why?
| | Middle Aged | 7 | 2024 | 645 | 0.280 |
Why?
| | Acute Kidney Injury | 2 | 2007 | 28 | 0.280 |
Why?
| | Uric Acid | 2 | 2005 | 6 | 0.270 |
Why?
| | Bone Density Conservation Agents | 3 | 2012 | 10 | 0.270 |
Why?
| | Membrane Proteins | 2 | 2006 | 53 | 0.270 |
Why?
| | Infant, Newborn | 6 | 2023 | 826 | 0.260 |
Why?
| | Birth Weight | 2 | 2023 | 28 | 0.250 |
Why?
| | Cohort Studies | 6 | 2023 | 281 | 0.250 |
Why?
| | Body Height | 1 | 2024 | 34 | 0.240 |
Why?
| | Reproducibility of Results | 3 | 2011 | 198 | 0.240 |
Why?
| | Paraffin | 1 | 2003 | 2 | 0.240 |
Why?
| | Urine | 1 | 2003 | 2 | 0.240 |
Why?
| | Age Factors | 3 | 2018 | 211 | 0.240 |
Why?
| | Protons | 1 | 2003 | 6 | 0.240 |
Why?
| | Circadian Rhythm | 1 | 2003 | 7 | 0.240 |
Why?
| | Mental Health | 1 | 2024 | 19 | 0.240 |
Why?
| | Dyslipidemias | 1 | 2024 | 15 | 0.230 |
Why?
| | Specimen Handling | 1 | 2003 | 17 | 0.230 |
Why?
| | Anxiety | 1 | 2024 | 50 | 0.230 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2024 | 41 | 0.230 |
Why?
| | Depression | 1 | 2024 | 68 | 0.230 |
Why?
| | Premature Birth | 1 | 2023 | 7 | 0.230 |
Why?
| | Recurrence | 5 | 2023 | 121 | 0.220 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 5 | 0.220 |
Why?
| | Gonadal Steroid Hormones | 1 | 2022 | 2 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 8 | 0.220 |
Why?
| | Longitudinal Studies | 4 | 2024 | 119 | 0.210 |
Why?
| | Fibroblast Growth Factors | 1 | 2022 | 30 | 0.210 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2002 | 2 | 0.210 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2001 | 6 | 0.200 |
Why?
| | Central Nervous System | 1 | 2001 | 9 | 0.200 |
Why?
| | Genetic Variation | 2 | 2020 | 166 | 0.200 |
Why?
| | Biopsy | 4 | 2023 | 63 | 0.200 |
Why?
| | Pneumonia | 1 | 2002 | 32 | 0.200 |
Why?
| | Proteins | 1 | 2001 | 27 | 0.200 |
Why?
| | Janus Kinase 2 | 3 | 2017 | 8 | 0.200 |
Why?
| | Organ Size | 1 | 2021 | 14 | 0.200 |
Why?
| | Genes, fos | 1 | 2021 | 1 | 0.200 |
Why?
| | Lymphoid Enhancer-Binding Factor 1 | 1 | 2021 | 1 | 0.200 |
Why?
| | Transcription Factor 3 | 1 | 2021 | 1 | 0.200 |
Why?
| | Lac Operon | 1 | 2021 | 2 | 0.200 |
Why?
| | Cell Cycle | 1 | 2021 | 18 | 0.200 |
Why?
| | Regression Analysis | 2 | 2011 | 52 | 0.200 |
Why?
| | Animals, Newborn | 1 | 2021 | 27 | 0.200 |
Why?
| | Retrospective Studies | 8 | 2023 | 1337 | 0.190 |
Why?
| | Databases, Genetic | 1 | 2021 | 27 | 0.190 |
Why?
| | Apoptosis | 1 | 2021 | 49 | 0.190 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 50 | 0.190 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-2 | 1 | 2020 | 1 | 0.190 |
Why?
| | Complement C1q | 1 | 2000 | 3 | 0.190 |
Why?
| | Peritoneal Dialysis | 3 | 2007 | 156 | 0.190 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 5 | 0.190 |
Why?
| | Pregnancy | 1 | 2021 | 212 | 0.180 |
Why?
| | Pain | 2 | 2012 | 56 | 0.180 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 1999 | 1 | 0.180 |
Why?
| | Bone Diseases | 1 | 1999 | 4 | 0.180 |
Why?
| | Mycophenolic Acid | 2 | 2012 | 6 | 0.180 |
Why?
| | Cyclosporine | 2 | 2012 | 6 | 0.180 |
Why?
| | Lymphoproliferative Disorders | 1 | 1999 | 4 | 0.180 |
Why?
| | Follow-Up Studies | 6 | 2019 | 329 | 0.180 |
Why?
| | Osteogenesis Imperfecta | 1 | 1999 | 8 | 0.180 |
Why?
| | Genes, Dominant | 1 | 1999 | 5 | 0.170 |
Why?
| | Bezoars | 1 | 1999 | 2 | 0.170 |
Why?
| | Candidiasis | 1 | 1999 | 5 | 0.170 |
Why?
| | Polycystic Kidney Diseases | 1 | 1999 | 3 | 0.170 |
Why?
| | Mutation, Missense | 3 | 2014 | 28 | 0.170 |
Why?
| | Edema | 1 | 2019 | 7 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 33 | 0.170 |
Why?
| | Immunohistochemistry | 3 | 2006 | 47 | 0.170 |
Why?
| | Anemia, Sickle Cell | 1 | 2019 | 17 | 0.170 |
Why?
| | Bone Resorption | 2 | 2012 | 2 | 0.170 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 3 | 0.170 |
Why?
| | Spiro Compounds | 1 | 2018 | 1 | 0.170 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2018 | 1 | 0.170 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2018 | 6 | 0.170 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2018 | 3 | 0.160 |
Why?
| | Sulfonamides | 1 | 2018 | 10 | 0.160 |
Why?
| | Renin-Angiotensin System | 1 | 2018 | 5 | 0.160 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 15 | 0.160 |
Why?
| | Receptors, Calcitriol | 2 | 2010 | 9 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2018 | 17 | 0.160 |
Why?
| | Aging | 1 | 2018 | 39 | 0.160 |
Why?
| | Hyperparathyroidism | 1 | 2018 | 1 | 0.160 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2018 | 1 | 0.160 |
Why?
| | Graft Rejection | 1 | 2018 | 32 | 0.160 |
Why?
| | Quality of Life | 1 | 2019 | 139 | 0.150 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 14 | 0.150 |
Why?
| | Reference Values | 2 | 2011 | 43 | 0.150 |
Why?
| | Rats, Sprague-Dawley | 2 | 2015 | 47 | 0.150 |
Why?
| | Prospective Studies | 4 | 2023 | 547 | 0.150 |
Why?
| | Rats | 2 | 2015 | 112 | 0.150 |
Why?
| | United States | 3 | 2017 | 670 | 0.150 |
Why?
| | Ambulatory Care | 1 | 2017 | 45 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 122 | 0.140 |
Why?
| | Chromogranins | 1 | 2015 | 2 | 0.140 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2015 | 2 | 0.140 |
Why?
| | Calcitriol | 1 | 2015 | 6 | 0.140 |
Why?
| | Phosphates | 1 | 2015 | 13 | 0.130 |
Why?
| | Exons | 1 | 2015 | 35 | 0.130 |
Why?
| | Dietary Supplements | 1 | 2015 | 25 | 0.130 |
Why?
| | Galactose | 1 | 2015 | 1 | 0.130 |
Why?
| | Adalimumab | 1 | 2015 | 2 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 7 | 0.130 |
Why?
| | Blood Cells | 1 | 2015 | 2 | 0.130 |
Why?
| | Glomerular Filtration Barrier | 1 | 2015 | 1 | 0.130 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 7 | 0.130 |
Why?
| | Cyclins | 2 | 2006 | 2 | 0.130 |
Why?
| | Cyclin A | 2 | 2006 | 2 | 0.130 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2006 | 2 | 0.130 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 2 | 2006 | 2 | 0.130 |
Why?
| | Cyclin D | 2 | 2006 | 2 | 0.130 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2014 | 1 | 0.130 |
Why?
| | Alcohol Dehydrogenase | 1 | 2014 | 4 | 0.130 |
Why?
| | Ethanol | 1 | 2014 | 7 | 0.130 |
Why?
| | Age of Onset | 3 | 2023 | 28 | 0.120 |
Why?
| | Phenotype | 1 | 2015 | 256 | 0.120 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2014 | 4 | 0.120 |
Why?
| | DNA Methylation | 1 | 2015 | 111 | 0.120 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 2 | 0.120 |
Why?
| | Giant Cell Tumors | 2 | 1992 | 2 | 0.120 |
Why?
| | Bone Transplantation | 2 | 1992 | 9 | 0.120 |
Why?
| | Bone Neoplasms | 2 | 2012 | 25 | 0.120 |
Why?
| | Genotype | 3 | 2023 | 408 | 0.120 |
Why?
| | Pain Measurement | 2 | 2012 | 48 | 0.120 |
Why?
| | RNA, Messenger | 1 | 2014 | 115 | 0.120 |
Why?
| | Filtration | 1 | 2013 | 2 | 0.120 |
Why?
| | Nephrons | 1 | 2013 | 2 | 0.120 |
Why?
| | Aged | 3 | 2019 | 411 | 0.120 |
Why?
| | Rituximab | 2 | 2024 | 4 | 0.120 |
Why?
| | Urogenital Abnormalities | 1 | 2013 | 12 | 0.120 |
Why?
| | Neptune | 2 | 2023 | 2 | 0.110 |
Why?
| | Prognosis | 3 | 2018 | 216 | 0.110 |
Why?
| | Diffusion Chambers, Culture | 1 | 2012 | 1 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 8 | 0.110 |
Why?
| | Cell Division | 2 | 2003 | 12 | 0.110 |
Why?
| | Incidence | 3 | 2017 | 134 | 0.110 |
Why?
| | Alleles | 3 | 2021 | 213 | 0.110 |
Why?
| | Osteoclasts | 1 | 2012 | 4 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 41 | 0.110 |
Why?
| | Dexamethasone | 1 | 2012 | 29 | 0.110 |
Why?
| | Cartilage | 1 | 2012 | 2 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 103 | 0.100 |
Why?
| | Bone Cysts | 1 | 1992 | 1 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2009 | 102 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2024 | 31 | 0.100 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 36 | 0.100 |
Why?
| | Drug Resistance | 3 | 2018 | 7 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2018 | 96 | 0.100 |
Why?
| | Alopecia | 1 | 2010 | 2 | 0.090 |
Why?
| | Infant, Premature | 1 | 2010 | 86 | 0.090 |
Why?
| | Likelihood Functions | 1 | 2009 | 6 | 0.090 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 2 | 0.080 |
Why?
| | Placebos | 1 | 2009 | 4 | 0.080 |
Why?
| | Oxycodone | 1 | 2009 | 4 | 0.080 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2009 | 1 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2009 | 16 | 0.080 |
Why?
| | Radiopharmaceuticals | 1 | 2009 | 5 | 0.080 |
Why?
| | Calibration | 1 | 2009 | 7 | 0.080 |
Why?
| | Kinetics | 1 | 2009 | 34 | 0.080 |
Why?
| | Acetaminophen | 1 | 2009 | 18 | 0.080 |
Why?
| | Loop of Henle | 1 | 2007 | 1 | 0.070 |
Why?
| | Intestinal Absorption | 1 | 2007 | 2 | 0.070 |
Why?
| | DNA Mutational Analysis | 2 | 2010 | 43 | 0.070 |
Why?
| | Base Sequence | 2 | 2010 | 87 | 0.070 |
Why?
| | Chemistry, Clinical | 1 | 2007 | 2 | 0.070 |
Why?
| | Drainage | 1 | 2007 | 35 | 0.070 |
Why?
| | Anions | 1 | 2006 | 1 | 0.070 |
Why?
| | Osmolar Concentration | 1 | 2006 | 5 | 0.070 |
Why?
| | Acute Disease | 2 | 2008 | 77 | 0.070 |
Why?
| | Receptors, Cytokine | 2 | 2017 | 2 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 1 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 20 | 0.070 |
Why?
| | Permeability | 2 | 2017 | 7 | 0.070 |
Why?
| | Midwestern United States | 2 | 2019 | 35 | 0.070 |
Why?
| | Sex Distribution | 2 | 2017 | 17 | 0.070 |
Why?
| | G1 Phase | 1 | 2006 | 2 | 0.070 |
Why?
| | S Phase | 1 | 2006 | 3 | 0.070 |
Why?
| | Age Distribution | 2 | 2017 | 32 | 0.070 |
Why?
| | Capillary Permeability | 1 | 2006 | 3 | 0.070 |
Why?
| | Cyclophosphamide | 1 | 2006 | 8 | 0.070 |
Why?
| | Hypoalbuminemia | 1 | 2006 | 4 | 0.070 |
Why?
| | Prednisone | 1 | 2006 | 12 | 0.070 |
Why?
| | Autoantibodies | 1 | 2006 | 10 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2006 | 34 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 23 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2017 | 216 | 0.070 |
Why?
| | Phosphorylation | 2 | 2015 | 21 | 0.060 |
Why?
| | Cystinuria | 1 | 2005 | 1 | 0.060 |
Why?
| | Xanthine | 1 | 2005 | 1 | 0.060 |
Why?
| | Mutation | 1 | 2006 | 213 | 0.060 |
Why?
| | Food | 1 | 2005 | 17 | 0.060 |
Why?
| | Lipids | 1 | 2024 | 8 | 0.060 |
Why?
| | Growth Disorders | 1 | 2024 | 25 | 0.060 |
Why?
| | Pediatrics | 1 | 2006 | 183 | 0.060 |
Why?
| | Refrigeration | 1 | 2003 | 1 | 0.060 |
Why?
| | Syringes | 1 | 2003 | 1 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2003 | 21 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2024 | 32 | 0.060 |
Why?
| | Densitometry | 1 | 2003 | 1 | 0.060 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2003 | 2 | 0.060 |
Why?
| | Prevalence | 1 | 2024 | 150 | 0.060 |
Why?
| | Patient Transfer | 1 | 2023 | 8 | 0.060 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 3 | 0.060 |
Why?
| | Infant, Low Birth Weight | 1 | 2023 | 14 | 0.060 |
Why?
| | Transition to Adult Care | 1 | 2023 | 18 | 0.060 |
Why?
| | Apolipoproteins | 1 | 2023 | 5 | 0.060 |
Why?
| | Cotinine | 1 | 2023 | 4 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2003 | 15 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2013 | 37 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2022 | 1 | 0.050 |
Why?
| | Tumor Necrosis Factors | 1 | 2022 | 1 | 0.050 |
Why?
| | Biological Assay | 1 | 2022 | 3 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2003 | 148 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2003 | 52 | 0.050 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2002 | 17 | 0.050 |
Why?
| | Complement C3 | 1 | 2002 | 3 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2023 | 110 | 0.050 |
Why?
| | Thioguanine | 1 | 2002 | 8 | 0.050 |
Why?
| | Erythrocytes | 1 | 2002 | 11 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2002 | 31 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 78 | 0.050 |
Why?
| | DNA | 1 | 2002 | 44 | 0.050 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2001 | 4 | 0.050 |
Why?
| | Syndrome | 1 | 2001 | 34 | 0.050 |
Why?
| | Medication Adherence | 1 | 2021 | 21 | 0.050 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2021 | 1 | 0.050 |
Why?
| | Glomerular Mesangium | 1 | 2001 | 1 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2000 | 2 | 0.050 |
Why?
| | Length of Stay | 1 | 2002 | 243 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2020 | 60 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 275 | 0.050 |
Why?
| | Epstein-Barr Virus Infections | 1 | 1999 | 3 | 0.040 |
Why?
| | Ganciclovir | 1 | 1999 | 3 | 0.040 |
Why?
| | Administration, Oral | 1 | 1999 | 58 | 0.040 |
Why?
| | Urography | 1 | 1999 | 2 | 0.040 |
Why?
| | Ureteral Obstruction | 1 | 1999 | 5 | 0.040 |
Why?
| | Antiviral Agents | 1 | 1999 | 26 | 0.040 |
Why?
| | Endoscopy | 1 | 1999 | 16 | 0.040 |
Why?
| | Antifungal Agents | 1 | 1999 | 13 | 0.040 |
Why?
| | Ultrasonography | 1 | 1999 | 49 | 0.040 |
Why?
| | Self Report | 1 | 2019 | 41 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2018 | 45 | 0.040 |
Why?
| | Preoperative Period | 1 | 2018 | 5 | 0.040 |
Why?
| | Renal Elimination | 1 | 2018 | 1 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2018 | 2 | 0.040 |
Why?
| | Postoperative Complications | 1 | 1999 | 202 | 0.040 |
Why?
| | Calcineurin Inhibitors | 1 | 2017 | 2 | 0.040 |
Why?
| | Hypertension, Malignant | 1 | 2017 | 1 | 0.040 |
Why?
| | Observer Variation | 1 | 2017 | 14 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1999 | 113 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 37 | 0.040 |
Why?
| | Risk Assessment | 1 | 2017 | 136 | 0.040 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2015 | 3 | 0.030 |
Why?
| | Actin Cytoskeleton | 1 | 2015 | 1 | 0.030 |
Why?
| | Kidney Cortex | 1 | 2015 | 2 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2015 | 6 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2015 | 52 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2015 | 24 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2015 | 3 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 4 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2015 | 3 | 0.030 |
Why?
| | Spleen | 1 | 2015 | 32 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 37 | 0.030 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2014 | 1 | 0.030 |
Why?
| | Puromycin | 1 | 2014 | 1 | 0.030 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 2014 | 4 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2014 | 5 | 0.030 |
Why?
| | Sri Lanka | 1 | 2014 | 1 | 0.030 |
Why?
| | Decalcification Technique | 2 | 1992 | 2 | 0.030 |
Why?
| | Radiography | 2 | 1992 | 49 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2014 | 110 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2013 | 25 | 0.030 |
Why?
| | Remission Induction | 1 | 2013 | 24 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2012 | 16 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 45 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 44 | 0.030 |
Why?
| | Curettage | 1 | 1992 | 1 | 0.030 |
Why?
| | Fibrous Dysplasia of Bone | 1 | 1992 | 1 | 0.030 |
Why?
| | Fibroma | 1 | 1992 | 2 | 0.030 |
Why?
| | Osteoma | 1 | 1992 | 3 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2012 | 186 | 0.020 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2010 | 3 | 0.020 |
Why?
| | COS Cells | 1 | 2010 | 19 | 0.020 |
Why?
| | Steroid Hydroxylases | 1 | 2010 | 13 | 0.020 |
Why?
| | Binding Sites | 1 | 2010 | 27 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 36 | 0.020 |
Why?
| | Fibroblasts | 1 | 2010 | 26 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 78 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2010 | 84 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2008 | 14 | 0.020 |
Why?
| | Catheters, Indwelling | 1 | 2007 | 30 | 0.020 |
Why?
| | Time | 1 | 2006 | 7 | 0.020 |
Why?
| | Osteogenesis | 1 | 2006 | 6 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 1988 | 21 | 0.000 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1988 | 33 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|